BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230517T160000
DTEND;TZID=Europe/Brussels:20230517T163000
DTSTAMP:20260526T214420
CREATED:20230516T082719Z
LAST-MODIFIED:20230516T082807Z
UID:6226-1684339200-1684341000@www.europabio.org
SUMMARY:EU Healthcare and Pharmaceutical Policy in 2023: What You Need to Know
DESCRIPTION:From the ongoing revision of the EU pharmaceutical legislation package and addressing critical supply issues to the impact of the recent Medical Device Regulation transition period extension\, the challenges in EU healthcare and pharmaceutical policy are ever-evolving. Plus\, with the implementation of critical files\, such as the European Health Data Space (EHDS) and the Substances of Human Origin (SoHo) regulation\, it’s vital for organizations in this market to stay up-to-date with the latest policy and regulatory developments. \n\n\n\nTune in on May 17 at 4 pm CEST | 10 am EDT for a 30-minute recorded webinar that will delve into the latest updates in legislation and regulation that are shaping the future of healthcare\, pharmaceutical\, and medical device industries in Europe to help you navigate the next steps in this policy landscape. \n\n\n\nExperts will discuss: \n\n\n\n\nThe ongoing revision of EU pharmaceutical legislation\n\n\n\nTackling critical supply issues in pharmaceuticals and medical devices\n\n\n\nThe impact of the Medical Device Regulation transition period extension\n\n\n\nProposed and upcoming critical files you should be monitoring\n\n\n\nThe future of EU healthcare policy in 2023 and beyond\n\n\n\n\nFeatured speakers: \n\n\n\n\nAdrien Samson\, healthcare policy & public affairs senior manager\, EuropaBio\n\n\n\nJelle Verheij\, policy analyst – health and pharmaceuticals policy\, EU Issue Tracker\n\n\n\nModerator: Geraint Edwards\, managing director of FiscalNote Brussels\n\n\n\n\n\nMore Details
URL:https://www.europabio.org/event/eu-healthcare-and-pharmaceutical-policy-in-2023-what-you-need-to-know/
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/General-Promo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230427T140000
DTEND;TZID=Europe/Brussels:20230427T151500
DTSTAMP:20260526T214420
CREATED:20230322T114230Z
LAST-MODIFIED:20230412T135959Z
UID:6092-1682604000-1682608500@www.europabio.org
SUMMARY:EuropaBio Biomanufacturing Policy Summit 2023: Where next for Europe?
DESCRIPTION:Summit outcomes and next steps \n\n\n\n\n\nOn 15th March\, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels\, with the aim of setting the vision for Europe’s global innovation\, competitiveness\, and sustainability on biomanufacturing\, while raising awareness among policy-makers. The Summit established a starting point\, a first step for a long journey that needs to be traveled by all stakeholders in Europe – SMEs\, large companies\, expert services\, and EU institutions – and which has already started in other parts of the world. \n\n\n\n80 attendees from industry\, national associations\, and stakeholders across the public and private spectrum presented\, debated\, and proposed.  In a fast-moving industrial transition\, calls for visionary policies\, enabling regulation\, and urgent action were some of the key takeaways from the summit. You can see the March 15th Summit agenda here. \n\n\n\nWould you like to find out more? \n\n\n\nJoin us on April 27 between 14:00 – 15:15 CET for a summit presentation and follow-up and add your voice to the discussion. This webinar will wrap up the main outcomes of the summit and lay the groundwork for future discussions. \n\n\n\nBiomanufacturing is key to the digital and green transitions and to securing a competitive and resilient future for Europe. Stay tuned for Europe’s future in biomanufacturing! \n\n\n\nAGENDA\n\n\n\n14:00: Welcome and introduction – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n14:10: Biomanufacturing Policy Summit report presentation – Virginia Claudio\, Sr Adviser & Programme Manager\, EuropaBio \n\n\n\nThe report presentation summarises the summit outcomes and builds policy recommendations for the development of the Biomanufacturing landscape in Europe. \n\n\n\n14:20: Report perspectives & reflections from healthcare and biotech industries\, and national associations – Sarah Moundir\, EU Public Affairs Senior Manager\, Novartis | Gwenael Servant\, Board Executive\, Abolis | Inga Matijosyte\, Vice President\, LithuaniaBIO \n\n\n\nA diverse group of stakeholders representing the wide spectrum of Biomanufacturing shares their views over the report outcomes\, as well as the priorities for their companies and organisations. \n\n\n\n14:50: Discussion and Q&A with the audience \n\n\n\nA discussion based on questions from the audience with a focus on the next steps for policy making on Biomanufacturing. \n\n\n\n15:10: Close – Closing remarks. \n\n\n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2023-where-next-for-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/SM1-Quotes-Key-Messages-600-×-200px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230424T100000
DTEND;TZID=Europe/Brussels:20230425T190000
DTSTAMP:20260526T214420
CREATED:20230111T144716Z
LAST-MODIFIED:20230111T144717Z
UID:5648-1682330400-1682449200@www.europabio.org
SUMMARY:Swiss Biotech Day 2023
DESCRIPTION:The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed date in the community’s calendar. In 2022\, the conference demonstrated the impressive growth of the Swiss biotech industry and presented an exciting program with ideal networking opportunities for over 1\,100 participants across the globe. \n\n\n\nIn 2023\, the Swiss Biotech Day will again offer high-level experts from the life science industry the space to network\, discuss and discover trends in R&D\, manufacturing\, data management\, artificial intelligence and innovative financing over one and a half days. In addition\, international biotech delegations can take part in the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments\, public-private partnerships\, research and development collaborations and exchange of talent.  \n\n\n\nWe hope to see you in Basel on April 24-25\, 2023 in person again. \n\n\n\nWhat to expect: \n\n\n\n\nMeet 1.000+ senior experts from the life science industry\n\n\n\n70+ exhibitors and global village with international delegations from all over the world\n\n\n\nSwiss Biotech Success Stories Awards\n\n\n\nInnovative biotech start-ups and medium-sized biotech companies\n\n\n\nThematically focused panel discussions\n\n\n\nSwiss Biotech Report 2023\n\n\n\nPre-scheduled one-to-one partnering meetings\n\n\n\nGeneral Assembly of the Swiss Biotech Association\n\n\n\n\n\nMore information
URL:https://www.europabio.org/event/swiss-biotech-day-2023/
LOCATION:Congress Center Basel\, Messeplatz 21\, Basel\, 4058\, Switzerland
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230418T150000
DTEND;TZID=Europe/Brussels:20230418T160000
DTSTAMP:20260526T214420
CREATED:20230124T170639Z
LAST-MODIFIED:20230406T134218Z
UID:5708-1681830000-1681833600@www.europabio.org
SUMMARY:Development of Orphan Biologics: Challenges and Opportunities
DESCRIPTION:Webinar sponsored by Catalent \n\n\n\n\n\n\n\n\n\nThe development of therapies for rare diseases comes with distinct challenges\, including patient recruitment\, setting meaningful clinical endpoints\, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy. \n\n\n\nFor biologic products (growth factors\, monoclonal antibodies\, other complex proteins)\, development and production costs tend to be higher due to the complexity of the drug substance. To manage costs\, the clinical development and manufacturing and Chemistry\, Manufacturing and Controls (CMC) teams need to be aligned to ensure drug product is delivered on time to meet clinical trial needs. \n\n\n\nThese challenges sit within a wider regulatory and legislative framework for orphan medicinal products (OMPs) that defines whether companies can successfully develop a novel product to market and thus the decisions made for selecting therapeutics and target diseases early in development. \n\n\n\nDuring this webinar\, speakers cover aspects of clinical trial design for orphan biologics products\, key strategies for ensuring clinical trial supply throughout clinical development and the regulatory and legislative framework for delivery to patients.Key Learning Objectives \n\n\n\n\nConsiderations in identifying meaningful clinical endpoints for orphan diseases\n\n\n\nOrphan clinical trial design considerations and strategies to ensure sufficient patient recruitment\n\n\n\nManufacturing and clinical supply strategies to ensure supply of clinical trial materials while collecting data needed to support NDA submission\n\n\n\nRegulatory and legislative frameworks that guide decision making for innovation in rare diseases\n\n\n\n\nAgenda \n\n\n\n15:00: Welcome and introduction – Claire Skentelbery\, Director General EuropaBio \n\n\n\n15:05: Current Development of Orphan Drugs in Europe – Matthias Schoenermark\, Professor\, President and CEO\, SKC Beratungsgesellschaft mbH \n\n\n\nProf. Schönermark opens the session with an overview of the current status of orphan drug development in the EU. He discusses the main challenges for market entry of new orphan drugs into the EU market and highlights key recommendations to drug developers to address these challenges. \n\n\n\n15:20: Orphan Biologics and CGT Development – CMC and Clinical Trial Supply Considerations – Wai Lam Ling\, Ph.D.\, Vice President\, Science and Technology\,  Catalent \n\n\n\nDr. Ling discusses the difference in CMC challenges encountered during an orphan biologics vs CGT programme\, with a focus on product quality as the most significant hurdle to approval. She addresses manufacturing approaches to ensure regulatory compliance and factors behind a successful product\, particularly robust\, reproducible and cost-effective pathways. Finally\, supply chain liabilities are discussed\, with risks to production of biologics and their clinical supply. \n\n\n\n15:45: Successful Strategies and Business Model For Companies Bringing Their Orphan Drug To Market –Thomas Bols\, Head of Government Affairs and Patient Advocacy\, EMEA & APAC\, PTC Therapeutics \n\n\n\nThomas Bols addresses the spectrum of opportunities and barriers for innovation within orphan drug development\, particularly across different regulatory territories\, and the critical role of smaller companies in addressing unmet medical needs. He focuses on the legislative and regulatory pathways that exist in Europe for orphan drugs and the potential impact of the upcoming pharmaceutical and OMP legislation revisions for company innovation and patient benefits. \n\n\n\n16:00: Close \n\n\n\n\nRegister here
URL:https://www.europabio.org/event/development-of-orphan-biologics-challenges-and-opportunities/
LOCATION:Catalent
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-5.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230418T100000
DTEND;TZID=Europe/Brussels:20230419T190000
DTSTAMP:20260526T214420
CREATED:20230110T150742Z
LAST-MODIFIED:20230110T151000Z
UID:5629-1681812000-1681930800@www.europabio.org
SUMMARY:CEBioForum 2023
DESCRIPTION:CEBioForum is a brand that has been creating a business environment related to biotechnology for over 20 years\, organizing the most important event of this type in the industry\, dedicated to the development of biotechnology in Poland and Europe \n\n\n\nCEBioForum 2023 will take place on April 18-19 in Warsaw \n\n\n\nBecause we strongly believe that networking is the basis for building lasting business relationships\, CEBioForum 2023 is held only face-to-face\, giving you a chance to make new connections with business partners\, scientists and decision makers from the government\, who contribute to biotech development in Poland and other CEE countries. \n\n\n\nCEBioForum 2023 is more then discussion panels\, networking and the opportunity to present your company. During the conference banquete\, we will honor outstanding people and companies with CEBioForum Awards 2023. \n\n\n\nSo save the date 18-19th of April and be with us in Warsaw at CEBioForum 2023. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/cebioforum-2023/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230328T100000
DTEND;TZID=Europe/Brussels:20230329T190000
DTSTAMP:20260526T214420
CREATED:20230320T155641Z
LAST-MODIFIED:20230320T155643Z
UID:6060-1679997600-1680116400@www.europabio.org
SUMMARY:German Biotech Days 2023
DESCRIPTION:Germany’s largest biotech event\, the German Biotechnology Days 2023 (Deutsche Biotechnologietage\, DBT)\, will take place on March 28th and 29th in Wiesbaden. The event is the national forum for the German biotechnology industry. The DBT brings together entrepreneurs with scientists and partners from politics\, funding institutions and administration. The two-day program highlights the diverse fields of application and the potential of biotechnology\, from health research to the bioeconomy. \n\n\n\nThe German Biotechnology Days are jointly organised by BIO Deutschland and the Council of German BioRegions. The host region for 2023 is Technologieland Hessen from Wiesbaden\, and we were able to win Infectognostics Forschungscampus Jena as another partner region. \n\n\n\n\nMore information
URL:https://www.europabio.org/event/german-biotech-days-2023/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/Event-Page-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230315T130000
DTEND;TZID=Europe/Brussels:20230315T190000
DTSTAMP:20260526T214420
CREATED:20221114T094047Z
LAST-MODIFIED:20230308T114450Z
UID:5505-1678885200-1678906800@www.europabio.org
SUMMARY:Biomanufacturing Platform - Policy Summit 2023
DESCRIPTION:EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation\, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for its understanding and recognition within policy. \n\n\n\nThe half day meeting will bring together Members and invited stakeholders from across the policy\, finance\, trade\, skills and regulatory spectrum surrounding biomanufacturing. \n\n\n\nDiscussion will address what biomanufacturing looks like across sectors and the roles played by SMEs\, large companies and expert services. The economic and skills footprint will be reviewed\, plus how it sits within Europe’s twin pillars of green and digital transition within the industrial strategy. Finally\, it can start to address how policy shapes and facilitates biomanufacture and Europe’s global position for such a transformative technology in action. \n\n\n\nFrom the first Summit\, a roadmap for biomanufacture can be developed for Europe and creation of a long term discussion platform for stakeholders through the Platform. \n\n\n\nAgenda \n\n\n\n14:00Opening plenary14:00Welcome and introduction to the Biomanufacturing Policy Summit– Claire Skentelbery\, Director General\, EuropaBio14:10Biomanufacturing in Europe’s industrial transition– Peter Dröll\, Director Prosperity\, European Commission\, DG Research and Innovation14:30Biomanufacturing as a global transition: US Executive Order for Biomanufacturing in focus– Hilary Stiss\, Director\, International Affairs\, Biotechnology Innovation Organization (BIO) 14:45Quo vadis European Biomanufacturing innovation in a competitive\, globalized world– Wojciech Nowak\, Global Senior Director\, Novartis15:00I am Biomanufacturing: examples in action        ● Resilience\, sustainability and competitiveness: Biomanufacturing in daily life: Ute Schick\, Senior Vice President Research\, Development and Innovation (RDI)\, Nutrition & Care (NC-RDI)\, Evonik Operations GmbH       ● Growing SMEs: Biomanufacturing in the next generation of industry: Jeroen Hofenk\, Founder and Chief Science Officer\, SwiftPharma       ● The national landscape: Belgium’s economic development through biomanufacturing: Tineke Van hooland\, Deputy Secretary General Bio.be       ● Advanced healthcare: The role of biomanufacturing in reaching rare diseases: Philippe Moyen\, VP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics15:30Break16:00Parallel Breakout discussionsBreakout 1 – Advanced healthcare: Role and growth in Europe● Role in Europe’s pandemic response. Scale and flexibility of manufacture – planning\, delivering\, investment● Patient access to advanced therapies (including rare diseases).● Competitiveness and economic contributor across EuropeBreakout 2 – Resilience\, competitiveness and sustainability:● Transition of industrial process for sustainability●  Building resilience of supply● Innovation for competitiveness17:10Closing plenaryClosing panel discussion: Europe’s ambition and pathway for biomanufacturingStakeholders from across the biomanufacturing landscape look at the future for Europe within biomanufacturing. The industrial goals it must achieve\, the pathway towards those goals and how it can make use of the skills\, infrastructure and policy/regulatory frameworks through which Europe develops.Moderator: Kristin Schreiber (Director DG GROW)Panelists: Peter Wehrheim (Head of Unit RTD.B2)\, Kristin Thompson (COO EUREKARE)\, Nessa Fennelly (Senior Executive IBEC)\, Nicolo Giacomuzzi-Moore (Executive Director CBE JU)\, Stefaan Fiers (Head of Corporate Communication\, Public Affairs and Patient Advocacy Takeda Belgium).18:00Networking reception19:00Close\n\n\n\n \n\n\n\nSpeakers \n\n\n\n\n\n\n\n\n\n\nHilary Stiss\n\n\n\nDirector\, International Affairs\, BIO Program Director\, ICBA \n\n\n\nAs a Director for International Affairs at the Biotechnology Innovation Organization (BIO)\, Hilary is responsible for managing the industry association’s program of international advocacy and outreach for multilateral organizations. Hilary also manages the association’s engagement in Europe\, the Middle East\, North Africa\, Turkey and South Africa regions. In this position\, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also acts as Program Director for the International Council on Biotechnology Associations (ICBA). \n\n\n\n\n\n\n\n\n\n\n\n\n\nClaire Skentelbery\n\n\n\nClaire holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions\, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network\, working across sectors\, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017\, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Ute Schick\n\n\n\nSenior Vice President Research\, Development and Innovation\, Evonik \n\n\n\nDr. Schick has a 20-year track record in global profit and loss responsibility at CEO and Senior Manager level within Food\, Health\, Cosmetic Industry and Material Science. Before her current role with Evonik\, she held roles as SVP of Supply Chain and Business Processes and VP of new Growth Business. Prior to working at Evonik she held roles at DuPont and DSM. \n\n\n\n\n\n\n\n\n\n\n\n\n\nWojciech Nowak\n\n\n\nGroup Senior Director\, Global Governmental and Public Affairs\, Novartis International\, Switzerland.(Functional responsibility for ca. 30 countries incl. Western & Eastern Europe\, Central Asia). \n\n\n\nMulticultural\, inclusive and reflective leader who lived in 6 countries on 3 continents.Robust understanding of the global healthcare policies and life-sciences business with more than 20 years of experience in policy creation related to healthcare systems\, EU integration and global pharmaceutical market. \n\n\n\nStarted his career at the Ministry of Health (Poland) counselling policy leaders on European integration and healthcare matters\, followed by assignments in the Ministry of Health and Solidarity of the Republic of France (Paris\, France) and Health Directorate of the European Commission (DG SANCO\, Luxembourg). \n\n\n\nAfter joining private sector has been serving in a number of senior leadership roles of growingresponsibility in healthcare companies(GlaxoSmithKline\, Abbott\, Novartis) on country\, regional and global levels (Poland\, Belgium\, Switzerland). \n\n\n\nEducated in Poland\, United States\, Nederlands\, Switzerland\, with the background in political sciences\, international relations (Warsaw’s University\, Poland; European Institute of Public Administration\, Maastricht\, Nederlands) and business administration (IMD Business School Lausanne\, Switzerland) he is an expert in healthcare systems\, global healthcare policies and international business. \n\n\n\nPassionate about delivering access and best healthcare outcomes to patients around the World. \n\n\n\n\n\n\n\n\n\n\n\n\n\nTineke Van Hooland\n\n\n\nDeputy Secretary general of bio.be/essenscia  \n\n\n\nTineke Van Hooland is Deputy Secretary general of bio.be/essenscia\, the Belgian federation of companies active in life sciences & biotechnologies. She’s also a board member at EuropaBio\, the European Association for Bioindustries\, from which she also chairs the NAC\, National Associations Council. Prior to this\, Tineke held several leadership positions in biopharmaceutical companies at the corporate level over the past years. She has in-depth expertise in Governmental Affairs\, Market Access\, Communication and Patient Advocacy. Tineke graduated with High Distinction as Industrial Pharmacist from Ghent University in 2003. \n\n\n\nTineke is also the founder and CEO of epic 10\, a boutique external affairs consultancy firm\, and a respected board member in various other organizations.  She is known for her dynamic and no-nonsense approach\, is a female leadership advocate and has authored a number of opinion pieces on sustainable health policy and empowering women. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Schreiber\n\n\n\nKristin Schreiber leads the Directorate Ecosystems I: Chemicals\, Food\, Retail\, Health in DG GROW\, the Directorate General for Internal Market\, Industry\, Entrepreneurship and SMEs. \n\n\n\nPrior to her current Director position\, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021). \n\n\n\nKristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla\, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition. \n\n\n\n\n\n\n\n\n\n\n\n\n\nStefaan Fiers\n\n\n\nCorporate Communications\, Public Affairs and Patient Advocacy Takeda \n\n\n\nStefaan is Head of Corporate Communications\, Public Affairs and Patient Advocacy at Takeda Belgium\, one of the largest pharmaceutical companies in Belgium. With his team\, he secures the healthcare policy analysis\, engages with external stakeholders and coordinates the company’s communication strategy. Additionally\, he oversees Takeda’s public affairs activities in 24 mid-sized European countries. \n\n\n\nBefore joining Takeda in June 2020\, he was Director of Communications and Public Policy at the Belgian pharma industry association pharma.be and held public policy positions in the pharma industry\, at Bristol-Myers Squibb Belgium/Luxembourg and at MSD Belgium.Next to his activities at Takeda\, Stefaan is an Associate Professor in Public Affairs and Comparative Politics at KU Leuven\, a Board member of PACE (Public Affairs Community Europe)\, and the author of several books and peer-reviewed articles. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPhilippe Moyen\n\n\n\nVP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics \n\n\n\nFollowing a university focus on therapeutic systems\, followed by formulation and industrial development\, Philippe has worked across the biotechnology spectrum including Baxter Healthcare\, Fresenius Kabi\, Stallergenes Greer\, and PTC Therapeutics where he has a strong focus on operations. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Thompson\n\n\n\nVP\, Chief Business Officer \n\n\n\nKristin Thompson is a former head of strategic partnerships in microbiomes at Bioaster. Before that\, Dr. Thompson was senior BD manager at Famar and BD manager of the French biotech company DaVolterra. She worked in research at French INSERM and the University of North Carolina\, Chapel Hill. She holds a Ph.D. in molecular biology from the University of Ulm\, Germany. \n\n\n\n\n\n\n\n\n\n\n\n\n\nNicoló Giacomuzzi-Moore\n\n\n\nExecutive Director ad interim\, Circular Bio-based Industries Joint Undertaking \n\n\n\nNicoló Giacomuzzi-Moore is CBE JU’s Executive Director ad interim and Head of the Administration and Finance Unit. He has been working in European affairs for more than 20 years\, focusing on research and innovation policy\, program implementation\, and enterprise support. \n\n\n\nBefore joining BBI JU (now CBE JU) in 2016\, he worked for the European Commission’s Research Executive Agency\, where he was responsible for financial and legal support in implementing European research projects. \n\n\n\nNicoló also worked for an Italian business association dealing with industrial policy and stakeholder management at the EU level. He holds a degree in economics and international trade. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Dröll\n\n\n\nDirector for Prosperity\, Directorate-General for Research and Innovation \n\n\n\nPeter Dröll has been working in the European Commission for more than 20 years with positions in the environment\, enlargement negotiations\, industry policy\, innovation\, and research. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik. \n\n\n\nSince 2010 he is at the Directorate-General of Research and Innovation where he was first responsible for Innovation and then for Industrial Technologies. Following the re-orientation of DG Research and Innovation towards sustainability\, his competencies have been enlarged to include industrial R&I agendas and business intelligence as well as knowledge valorization policies. \n\n\n\nBefore joining the European Commission in 1991\, Peter worked as a lawyer in a German law firm. Peter is a lawyer by training with a doctorate degree in German constitutional law and European law. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJeroen Hofenk\n\n\n\nFounder and Chief Science Officer\, SwiftPharma \n\n\n\nJeroen is a serial entrepreneur and scientist with a background in bioengineering and genetics. He has broad experience in CRISPR engineering and various expression platforms including microbial-\, animal cell-based\, and plants.  In the last 10 years of his career\, Jeroen has built a strong track record in plant-made-pharmaceutical manufacturing and the optimization thereof. He obtained 3 patent grants and holds 13 pending patents to his name.” \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Wehrheim\n\n\n\nHead of the Unit for the “Bioeconomy and Food System” within the Directorate General for Research and Innovation of the European Commission in Brussels \n\n\n\nWhile working for Phil Hogan\, Commissioner for Agriculture and Rural Development\, he contributed to the EU Bioeconomy Strategy. From 2010 to 2018 he was Head of the Unit for Land Use and Climate Finance in DG Climate Action. Before 2004 Peter worked at the Universities of Bonn/DE\, Maryland/US (with a Heisenberg scholarship from the German Research Foundation)\, and Kiel/DE. He received his doctoral degree in agricultural economics from the University of Giessen\, Germany \n\n\n\n\n\n\nAbout the EuropaBio Biomanufacturing Platform \n\n\n\nThe Platform has the mission to represent biomanufacturing at the highest policy levels in Europe\, to ensure that it is visible and recognised within the industrial strategy and Europe’s green and digital transitions. \n\n\n\nEuropaBio’s Biomanufacturing Platform will address the policy and wider frameworks through which biomanufacturing is delivered.  Together with members and stakeholders\, it will address how economic growth\, employment and resilience are achieved through policy\, legal frameworks and regulation at EU and national levels. \n\n\n\nThe Summit will be open to EuropaBio Members and invited stakeholders. Please contact c.skentelbery@europabio.org for further information.
URL:https://www.europabio.org/event/biomanufacturing-platform-policy-summit-2023/
LOCATION:BIP Meeting Center – House of the Capital Region\, rue Royale 2-4\, Brussels\, 1000\, Belgium
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/SM1-Quotes-Key-Messages-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230228T110000
DTEND;TZID=Europe/Brussels:20230228T121500
DTSTAMP:20260526T214420
CREATED:20230117T135652Z
LAST-MODIFIED:20230118T100150Z
UID:5661-1677582000-1677586500@www.europabio.org
SUMMARY:SME BioForum: Rare diseases
DESCRIPTION:Rare Disease Day takes place on February 28th across the globe to raise awareness among policymakers and the public about rare diseases and their impact on patient’s lives and their families. \n\n\n\nBuilding on the latest SME BioForum on Advanced Therapy Medicinal Products (ATMPs)\, EuropaBio – the European Association for Bioindustries will mark this day by hosting an online\, invite-only SME BioForum solely dedicated to rare diseases. The event will take place from 11h00 to 12h15 CET. \n\n\n\nThe meeting is entirely SME driven. SME participants will connect with their peers\, share their experiences and discuss the current regulatory and incentives framework ahead of the revision of the pharmaceutical legislation and the legislation on orphan and pediatric medicines. \n\n\n\nIf you have any queries or want further details\, please get in touch with José Peres at j.peres@europabio.org. \n\n\n\n\nSME BioForum 2022 Report: Advanced Therapy Medicinal Products
URL:https://www.europabio.org/event/sme-bioforum-rare-diseases/
CATEGORIES:Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/SME-BioForum-Rare-Diseases_Event_Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230214T080000
DTEND;TZID=Europe/Brussels:20230215T170000
DTSTAMP:20260526T214420
CREATED:20230125T090903Z
LAST-MODIFIED:20230125T090904Z
UID:5720-1676361600-1676480400@www.europabio.org
SUMMARY:CLIB International Conference CIC2023
DESCRIPTION:From 14 to 15 February 2023\, the CLIB International Conference will take place in Düsseldorf\, Germany\, organised by CLIB – Cluster industrial biotechnology. Under the title ” Setting sail for industrial implementation” different sessions will debate how biotechnology help achieve the climate and sustainability goals. On the first day of the CIC2023\, the focus will be on levers in this monumental transformation\, highlighting where biotechnology can really make a difference: to harness sustainable resources\, to enable innovative processes\, and ultimately to close the carbon cycle. \n\n\n\nOn the second day\, CIC2023 will host the FARMŸNG satellite event\, focusing on zero-waste biorefineries. After inputs from this CBE JU flagship\, which is constructing the first-of-a-kind vertical large-scale insect farm\, other speakers will expand the scope towards other value chains\, discussing how zero-waste biorefineries can be planned\, built\, and sustainably supplied with feedstock\, all the while closing resource loops. A final keynote will focus on investing in scale-up projects and a holistic view on sustainability. \n\n\n\nAbout 200 participants are expected\, with representatives from industry\, a large number of national and international SMEs\, research institutions and stakeholders from politics and associations. In recent years\, the CIC has established itself as a platform to initiate partnerships along value chains in the bio and circular economy. \n\n\n\nAbout CIC – CLIB International Conference \n\n\n\nThis is the annual international conference of the Cluster Industrial Biotechnology\, initiated in 2009 and now in its 13th edition. The CIC has established itself as a platform to initiate partnerships along value chains in the bio and circular economy\, each year kicking off the biotech and bioeconomy conference circle early in the year. It has about 200 participants\, with representatives from industry\, a large number of national and international SMEs\, research institutions\, and stakeholders from politics and associations. \n\n\n\nAbout CLIB – Cluster Industrial Biotechnology \n\n\n\nCLIB (Cluster Industrial Biotechnology) is an international open innovation cluster of large companies\, SMEs\, academic institutes\, and universities\, as well as other stakeholders active in biotechnology and the circular bioeconomy as a whole. The cluster comprises over 100 members with a share of about 25 % international members. The overall goal of CLIB is to network stakeholders along and across value chains and to identify new opportunities for innovation\, projects\, and business. Through this\, the cluster develops cross-sectoral biotechnological solutions for sustainable processes and products. Pertinent project areas are identified by the CLIB team in conjunction with members in an iterative process. CLIB is a non-profit association\, with its members shaping the cluster’s interests and activities.
URL:https://www.europabio.org/event/clib-international-conference-cic2023/
LOCATION:Lindner Congress Hotel Düsseldorf\, Lütticher Str. 130\, Düsseldorf\, 40547\, Germany
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/CIC2023-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230131T090000
DTEND;TZID=Europe/Brussels:20230131T123000
DTSTAMP:20260526T214420
CREATED:20230125T152351Z
LAST-MODIFIED:20230125T154606Z
UID:5741-1675155600-1675168200@www.europabio.org
SUMMARY:EIC – EMA Info Day: Regulatory support for the development of innovative medicines and technologies
DESCRIPTION:Join this online Info Day and discover the wide range of support services that the European Medicines Agency (EMA) provides to researchers and SMEs in the pharmaceutical and med-tech sectors. \n\n\n\nThe European Innovation Council (EIC)  and the European Medicine Agency (EMA) invite you to attend the EIC-EMA Info Day on January 31\, 2023 to hear about the wide range of support services provided by EMA to researchers and SMEs active in research and innovation in the pharmaceutical and med-tech sectors.   \n\n\n\nDuring the online Info Day\, you will learn on how to engage with EMA at different development milestones\, and on the range of EMA support services including those targeting gene and cell therapies\, and orphan medicines. You will also hear about the benefits to apply to the Innovation Task Force (ITF) services\, PRIME and Scientific Advice as well as practical details on how to prepare and submit applications. Moreover\, you will hear real examples of advice given through these services and will testimonials from academic researchers and companies funded by the EIC Pathfinder and Accelerator programmes on their experience with EMA services.  \n\n\n\nEIC grantees and future EIC applicants are strongly encouraged to participate. The event is also open to researchers and SMEs funded by other EU programmes.   \n\n\n\nThis event is relevant if:   \n\n\n\n\nYou are you an innovator in the health-tech sector funded by the EIC or other EU programmes. \n\n\n\nYou are in the early development stage of a medical technology or pharmaceutical\, and have not considered regulatory aspects of your innovation and support from authorities.  \n\n\n\nYour medical technology or pharmaceutical development is more advanced and you want to learn how to best apply to European Medicines Agency (EMA) services such as PRIME or Scientific Advice. \n\n\n\n\n\nMore information
URL:https://www.europabio.org/event/eic-ema-info-day-regulatory-support-for-the-development-of-innovative-medicines-and-technologies/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-3-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230127T100000
DTEND;TZID=Europe/Brussels:20230127T120000
DTSTAMP:20260526T214420
CREATED:20230128T220033Z
LAST-MODIFIED:20230128T220327Z
UID:5768-1674813600-1674820800@www.europabio.org
SUMMARY:ESAB Webinar: Advances in the Analysis of Enzymatic Reactions
DESCRIPTION:PROGRAMME \n\n\n\n10:00 – Prof. Dr. Andrew J. deMello\, Institute for Chemical and Bioengineering\,Department of Chemistry and Applied Biosciences\, ETH Zürich\, CH 8093 Zurich\,Switzerland \n\n\n\n10:30 – Prof. Dr. Aurelio Hidalgo\, Universidad Autonoma de Madrid\, Center for Molecular Biology “Severo Ochoa“\, 28049-Madrid\, Spain \n\n\n\n11:00 – Prof. Dr. Gerhard K.E. Scriba\, Friedrich Schiller University\, Department of Pharmaceutical Chemistry\, Jena\, Germany \n\n\n\n11:30 – Dr. Neil MacKinnon\, Principal Investigator\, NMR Spectroscopy for Metabolomics and Signalling\, Institute of Microstructure Technology\, Karlsruhe Institute of Technology\, Campus North\, 76344 Eggenstein-Leopoldshafen\, Germany \n\n\n\n  \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/esab-webinar-advances-in-the-analysis-of-enzymatic-reactions/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/2023-01-26-16_14_23-.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221216T140000
DTEND;TZID=Europe/Brussels:20221216T160000
DTSTAMP:20260526T214420
CREATED:20221213T132138Z
LAST-MODIFIED:20221213T132140Z
UID:5590-1671199200-1671206400@www.europabio.org
SUMMARY:Biocatalytic Total Synthesis
DESCRIPTION:14:00 – 14:30 CETHarnessing the chemistry of plant natural product biosynthesis Prof. Dr. Sarah O’ConnorDepartment of Natural Product Biosynthesis\, Max Planck Institute for Chemical Ecology\, 07745 Jena\, Germany14:30 – 15:00 CETIntermolecular Diels-Alderases: Discovery and Applications in Natural Product Synthesis Prof. Dr. Xiaoguang LeiDepartment of Chemical Biology\, College of Chemistry and Molecular Engineering\, Peking University (PKU)\, Beijing 100871\, China15:00 – 15:30 CETEnzymatic Total Synthesis Approaches to Solve Enigmatic Biosynthetic Pathways and to Generate New Natural Product Analogues Prof. Jürgen Rohr\, Ph.D.\, FRSCCollege of Pharmacy\, University of Kentucky\, Lexington\, KY\, USA15:30 – 16:00 CETBiocatalysis in ring assembly and late-stage C-H functionalization of complex molecules Prof. Dr. David H. ShermanUniversity of Michigan\, Life Sciences Institute\, Departments of Medicinal Chemistry\, Chemistry\, Microbiology & Immunology\, Ann Arbor\, Michigan\, USA\n\n\n\nThis webinar is organised by ESAB – the European Society of Applied Biocatalysis\, which aims at promoting the development of Applied Biocatalysis throughout Europe.
URL:https://www.europabio.org/event/biocatalytic-total-synthesis/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/12/Event-Page.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221213T110000
DTEND;TZID=Europe/Brussels:20221213T121500
DTSTAMP:20260526T214420
CREATED:20221006T094946Z
LAST-MODIFIED:20221207T150549Z
UID:5169-1670929200-1670933700@www.europabio.org
SUMMARY:SME BioForum 2022 - the voice of SMEs for a competitive\, sustainable and healthy Europe
DESCRIPTION:EuropaBio – the European Association for Bioindustries is delighted to invite you to its first public SME BioForum event – “SME BioForum 2022 – the voice of SMEs for a competitive\, sustainable and healthy Europe.” \n\n\n\nThroughout 2022\, EuropaBio SME Platform\, representing Europe’s biotechnology SME community across healthcare and industrial biotechnology\, organised two inaugural SME BioForum sessions. The Platform gathered European SME executives to discuss the latest biotechnology commercial developments\, company challenges\, and how the European landscape impacts their ability to grow and deliver products and services to the market. \n\n\n\nIn our first session dedicated to Advanced Therapy Medicinal Products (ATMPs)\, SME executives discussed their main challenges to growth\, focusing on Europe’s Market fragmentation\, Regulatory pathways and other bottlenecks. The second SME BioForum session dedicated to Europe’s Green transition was hosted at EuropaBio’s flagship conference\, the European Forum for Industrial Biotechnology and the Bioeconomy in Vilnius\, Lithuania. In this session\, SME leaders discussed how European SMEs are driving Europe’s Green transition through Biomanufacturing\, Incentives for disruptive technologies and Data use and Digital applications. \n\n\n\nClosing this year\, EuropaBio will host this online event. Our SME participants and European policymakers will join us to present and debate the latest policy developments for ATMPs and Europe’s Green transition and share their recommendations for achieving a competitive\, sustainable\, healthy Europe. \n\n\n\nJoin us online for an engaging discussion on December 13\, 11h00 – 12h15 CET. \n\n\n\nSpeakers \n\n\n\n\nAhmed Bouzidi\, Managing Director Europe & VP International BD\, Trinomab Biotech\n\n\n\nLinda Dijkshoorn\, CEO\, EV Biotech\n\n\n\nPaschalia Koufokotsiou\, Pharmaceutical and Health Policy\, DG SANTE\, European Commission\n\n\n\nMiranda Lindsay-Fynn\, Commercial Director\, Bio-Sep\n\n\n\nAndré Meyer\, SME Envoy Network\, Outreach activities coordination\, DG GROW\, European Commission\n\n\n\nMaria Luísa Nolli\, EuropaBio SME Platform Chair\n\n\n\nClaire Skentelbery\, EuropaBio Director-General\n\n\n\nVivian Tseveleki\, COO\, Theracell\n\n\n\nTal Zeltzer\, CTO\, Phytolon\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/sme-bioforum-2022-the-voice-of-smes-for-a-competitive-sustainable-and-healthy-europe/
CATEGORIES:SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/10/Event-Page.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221206T090000
DTEND;TZID=Europe/Brussels:20221207T180000
DTSTAMP:20260526T214420
CREATED:20221116T144814Z
LAST-MODIFIED:20221116T145138Z
UID:5525-1670317200-1670436000@www.europabio.org
SUMMARY:17th European Bioplastics Conference
DESCRIPTION:The European Bioplastics Conference is Europe’s leading business and discussion forum within the global bioplastics sector. More and more brands and manufacturers are embracing the potential of biopolymers\, and policy makers are increasingly streamlining their efforts to create frameworks that benefit the growth of sustainable bio-industries. Now is the time to put bioplastics at the top of the agenda of a bio-based circular economy in Europe and beyond. \n\n\n\nThe registration for the 17th European Bioplastics Conference is now open and we are excited to welcome you on 6/7 December 2022 in Berlin or online.   \n\n\n\nThe hybrid format of this year’s event will allow you to join either in person at the Maritim proArte Hotel Berlin or comfortably log-in from your home base. Both of which offer unique networking opportunities  \n\n\n\nOf course\, we will also have an excellent exhibition on- and offline. Just choose the right type of booth to give your company visibility at the conference.  \n\n\n\n\nMore details
URL:https://www.europabio.org/event/17th-european-bioplastics-conference/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Vilnius-Statement-Event-600-×-260px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221201T143000
DTEND;TZID=Europe/Brussels:20221201T160000
DTSTAMP:20260526T214420
CREATED:20221117T151753Z
LAST-MODIFIED:20221121T110237Z
UID:5532-1669905000-1669910400@www.europabio.org
SUMMARY:EuropaBio Patient BioForum 2022: Toward a Common Understanding of Unmet Medical Needs
DESCRIPTION:EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. Addressing unmet medical need was outline as a central to the 2020 Pharmaceutical Strategy for Europe. One perceived shortcoming of the current legislative frameworks is insufficient stimulated development in some areas of ‘unmet medical need’ (UMN) such as antimicrobial resistance or rare diseases. The upcoming revision of the EU pharmaceutical legislation and orphan and paediatric legislation will aim at addressing “unmet medical needs”. \n\n\n\nA major hurdle to overcome is reaching a common understanding of unmet medical needs as stakeholders have different understanding of the concept based on different perceptions and expectations. Unmet medical need is scientific concept which can be used to identify patient and societal health needs and stimulate research activities. As science progresses\, and with it the knowledge to address unmet medical needs\, these needs will evolve over time from improving mortality\, modifying disease progression\, improving quality of life\, burden of the disease\, and potentially curing. \n\n\n\nBringing together multiple stakeholder groups\, including patients and industry\, the 2022 Patient BioForum is an opportunity to listen to patients’ understandings and experiences with unmet medical needs and facilitate progress towards a common understanding on unmet medical needs. \n\n\n\n \n\n\n\nSpeakers \n\n\n\n\nJoelle Khraiche\, EuropaBio\, Patient BioForum co-chair\n\n\n\n\n\nAnca Toma\, EPF\, Patient BioForum co-chair\n\n\n\n\n\nTobias S. Hagedorn\, Secretary of European Society for Phenylketonuria (ESPKU) and Managing Director of DIG PKU Germany\n\n\n\n\n\nPedro Franco\, Director Europe for Global Regulatory & Scientific Policy at Merck and Chair of EuropaBio’s OMP WG\n\n\n\n\nModerator \n\n\n\n\nAdrien Samson\, Healthcare Biotechnology Manager\, EuropaBio\n\n\n\n\n\nInvitation Only Event
URL:https://www.europabio.org/event/europabio-patient-bioforum-2022-toward-a-common-understanding-of-unmet-medical-needseuropabio-patient-bioforum-2022/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Patient-BioForum-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221130T083000
DTEND;TZID=Europe/Brussels:20221130T094500
DTSTAMP:20260526T214420
CREATED:20221103T154442Z
LAST-MODIFIED:20221114T101045Z
UID:5462-1669797000-1669801500@www.europabio.org
SUMMARY:EFIB 2022 Vilnius Statement wider launch
DESCRIPTION:Industrial Biotechnology for a sustainable society: a focus for 2023 and beyond Industrial biotechnology and biomanufacturing are recognised as being part of the response to some of today’s pressing global challenges. Delivering on EU Green Deal objectives whilst strengthening resilience and independence of European industries is increasingly critical.  \n\n\n\nThe inaugural EFIB Statement of October 2021 created a baseline for industrial biotechnology and bioeconomy vision in policy\, regulatory and landscape development. The EuropaBio’s EFIB Vilnius Statement of 2022 evolves to address this long-term vision and ambition within the context of challenges and needs over the next 12 months.  \n\n\n\nWe invite you to join us for a discussion on the role and potential of enabling technologies in the EU green transition\, with a focus on priorities for the shorter term and building up to the longer term.   \n\n\n\n \n\n\n\n\nInvitation Only Event
URL:https://www.europabio.org/event/efib-2022-vilnius-statement-wider-launch/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Vilnius-Statement-Event-600-×-260px-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221118T080000
DTEND;TZID=Europe/Brussels:20221119T170000
DTSTAMP:20260526T214420
CREATED:20220719T122304Z
LAST-MODIFIED:20220719T122306Z
UID:5000-1668758400-1668877200@www.europabio.org
SUMMARY:Scientix Conference
DESCRIPTION:The 4th Scientix Conference will take place online Friday 18 and Saturday 19 November 2022. The conference\, organised by European Schoolnet\, is one of the major science education networking events in Europe. With 2\,000 places available\, the goal of the conference is to provide an overview of the challenges and opportunities in science education in Europe and highlight the potential and possibilities that the Scientix community can bring about. The Scientix conference is also a unique opportunity to learn more about different STEM education projects in Europe\, deepening connections\, generating new ideas and inspiring science educators to foster creativity and enthusiasm for STEM education and share their expertise\, knowledge\, and best practices. \n\n\n\nTeachers\, educators\, policymakers\, science education researchers\, STEM professionals\, industry representatives\, and project managers are expected to participate in the conference. The conference programme will include invited high-level plenary sessions and round tables\, as well as presentation sessions in parallel with hands-on workshops. Posters will also be made available in an interactive online format. The new format of the conference is designed to create an interactive participant experience and offer different types of networking opportunities.
URL:https://www.europabio.org/event/scientix-conference/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/07/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221026T080000
DTEND;TZID=Europe/Brussels:20221027T170000
DTSTAMP:20260526T214420
CREATED:20220125T092223Z
LAST-MODIFIED:20220503T071025Z
UID:3722-1666771200-1666890000@www.europabio.org
SUMMARY:EFIB 2022
DESCRIPTION:EuropaBio is pleased to announce that the next edition of EFIB\, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title ‘Next generation economies: Industrial biotechnology for a sustainable society’\, will take place 26-27 October 2022 in Vilnius\, Lithuania. The Forum will be hosted by the Lithuanian Biotechnology Association (LBTA) together with Go Vilnius – the city’s official business and tourism development agency. \n\n\n\nNow in its 15th year\, EFIB will be dedicated to the innovation and commercial delivery of industrial biotechnology and the bioeconomy. EFIB will include a pre-conference science symposium ’’Gene Editing – From Research To Industry’’\, followed by two day Forum discussing how Industrial biotechnology contributes to transforming sectors and addresses consumer choices and needs. \n\n\n\nThe conference will network and showcase more than 500 delegates from the industry of all sizes\, from start-ups with the next transformative technology to multi-national producers scaling up to meet global demand for sustainable and novel products across sectors. It will also bring together the community that enables the industry to deliver\, including the researchers\, policy makers\, academia\, regulators\, global organisations and local leaders that build the framework for a sustainable society. \n\n\n\nFor the first time in 2022\, EFIB will host a post-conference meeting in the Permanent Representation of Lithuania to the EU in Brussels on 30 November\, which will deliver the EFIB Vilnius Statement to policy makers at the heart of Europe. \n\n\n\nThe registration for the EFIB 2022 will be opened in March. For more information visit our website and subscribe to our newsletter. \n\n\n\n\n\n\n\nAre you interested in sponsorship opportunities?EFIB offers an opportunity for sponsor organisations to achieve key objectives\, including sector messaging and advocacy or products and services visibility. For more information please contact Dr Claire Skentelbery\, Director General of EuropaBio (c.skentelbery@europabio.org).
URL:https://www.europabio.org/event/efib-2022/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/01/EFIB2022_Banner_SavetheDate_600x200px-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20221006T090000
DTEND;TZID=Europe/Brussels:20221006T180000
DTSTAMP:20260526T214420
CREATED:20220524T095238Z
LAST-MODIFIED:20220524T095511Z
UID:4755-1665046800-1665079200@www.europabio.org
SUMMARY:LignoValue Pilot Launch & Biorizon Networking Event 
DESCRIPTION:Get informed about the latest progress in the field of biobased aromatics\, and join the pre-arranged\, bilateral matchmaking sessions!  \n\n\n\nOn 6 October 2022\, Shared Research Center Biorizon & VITO’s LignoValue Pilot Plant will host a live networking event at VITO in Mol\, Flanders.\n\n\n\nMajor industrial players\, small to medium‑sized enterprises\, and research and technology organisations from all over the world will join Biorizon to discuss the latest progress in the field of bio-aromatics and to elaborate on opportunities to accelerate biobased business together. Over the past years\, this has evolved into a must-attend event for anyone who’s interested in renewable aromatics. Last edition attracted 305 participants from 28 countries.Program live event – 6 October: \n\n\n\nBus visit to the impressive LignoValue Pilot Plant at VITO in Mol\, Flanders.Live networkingFormal launch of the LignoValue Pilot Plant & a brief update by Biorizon.\n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/lignovalue-pilot-launch-biorizon-networking-event/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220929T140000
DTEND;TZID=Europe/Brussels:20220929T150000
DTSTAMP:20260526T214420
CREATED:20220830T122553Z
LAST-MODIFIED:20220922T103100Z
UID:5064-1664460000-1664463600@www.europabio.org
SUMMARY:European Biotech Week 2022: At the cutting edge of biotechnology for cardiovascular diseases: A World Heart Day special edition webinar
DESCRIPTION:Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients\, both in terms of innovative treatments\, but also via use of innovative prevention\, screening\, and testing measures. \n\n\n\nDuring this webinar\, which marks World Heart Day\, speakers will discuss how biomarker testing for genetically inherited risk factors for cardiovascular diseases is opening up new frontiers in healthcare\, and saving lives across the world. \n\n\n\nFeaturing speakers from the patient community\, research and academia\, and industry\, the conversation will also address the need to translate guidelines into practice\, and will end with an interactive Q&A. \n\n\n\nSpeakers: \n\n\n\nMarius Geanta\, Trustee and the Chair of the Policy Advisory Committee\, FH EuropeLena Lymperopoulou\, Global Policy Head Therapeutic Area Cardiovascular\, NovartisFlorian Kronenberg\, Full Professor and Head of the Institute of Genetic Epidemiology\, Medical University of InnsbruckJamie Wilkinson\, Healthcare Biotechnology Director\, EuropaBio\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-hc/
CATEGORIES:Biotech Week,EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-HC.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220927T140000
DTEND;TZID=Europe/Brussels:20220927T150000
DTSTAMP:20260526T214420
CREATED:20220830T105859Z
LAST-MODIFIED:20220914T134233Z
UID:5054-1664287200-1664290800@www.europabio.org
SUMMARY:European Biotech Week 2022: Innovative technologies in the EU green transition – spotlight on industrial biotechnology
DESCRIPTION:Industrial Biotechnology-derived products offer significant potential for contributing to overcoming many EU socio-economic and environmental challenges. It is not a new sector. On the contrary\, for thousands of years the power of microbes has been harnessed in food production and beverages. In the past century\, the applications for IB have expanded greatly with IB now providing living microorganisms and fermentation products that are used in sectors as diverse as food and feed\, agriculture\, detergents\, paper and pulp\, textiles\, fuels\, bioenergy\, and specialty chemicals. \n\n\n\nResearch and innovation are key drivers to accelerate the green transition. Indeed\, the EU Green Deal notes that “New technologies\, sustainable solutions and disruptive innovation are critical to achieve the objectives of the European Green Deal”. In this context\, a range of solutions will be needed. Alternatives to fossil-based products\, improved resource efficiency of industrial processes\, innovative food and feed are all targets where industrial biotechnology and bioeconomy innovation can deliver. \n\n\n\nThis webinar will discuss innovative solutions that can contribute towards the green transition\, with a focus on industrial biotechnology. It will zoom in on products of IB and their benefits and challenges\, also linking to the EU GMO regulatory framework and recent developments on new genomic techniques. \n\n\n\nSpeakers: \n\n\n\nMarc Leclerc\, Senior Regulatory Affairs Advisor\, NovozymesRachel Melnick\, Senior Scientific Program Manager\, Agriculture & Food Systems InstituteHans Genee\, Co-Founder and CSO\, Biosyntia\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-ib/
CATEGORIES:Biotech Week,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-IB.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220926T140000
DTEND;TZID=Europe/Brussels:20220926T151500
DTSTAMP:20260526T214420
CREATED:20220830T121819Z
LAST-MODIFIED:20220923T072206Z
UID:5060-1664200800-1664205300@www.europabio.org
SUMMARY:European Biotech Week 2022: Biotechnology for society\, sustainability and economies – transformative science for a changing world
DESCRIPTION:The 2022 European Biotech Week from EuropaBio opens with a look at how biotechnology is at the centre of Europe’s transformation to a healthy\, sustainable and competitive economy and society. \n\n\n\nJoin our Board Members from across Europe’s biotechnology spectrum to learn about biotech in action and its benefits in our every day lives\, as well as how it supports employment\, economic development and Europe’s place in the world. \n\n\n\nSpeakers: \n\n\n\nPatricia Malarkey\, Global Chief Innovation Officer\, DSMStefan Buchholz\, Senior VP R&D Nutrition and Care\, EvonikTom Bols\, Head of Government Affairs and Patient Advocacy\, PTC TherapeuticsAnnemeik Verkamman\, Managing Director\, HollandBio\n\n\n\n\nREGISTER NOW
URL:https://www.europabio.org/event/european-biotech-week-2022-biotechnology-for-society-sustainability-and-economies-transformative-science-for-a-changing-world/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Events-Template-600-×-200px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220926T080000
DTEND;TZID=Europe/Brussels:20221002T170000
DTSTAMP:20260526T214420
CREATED:20220406T072315Z
LAST-MODIFIED:20220503T075116Z
UID:4295-1664179200-1664730000@www.europabio.org
SUMMARY:European Biotech Week 2022
DESCRIPTION:From the clothes we wear and how we wash them\, the food we eat and the sources it comes from\, the medicine we use to keep us healthy and even to the fuel we use to take us where we need to go\, biotechnology plays an invaluable role in meeting our needs.The European Biotech Week – a week-long series of events\, taking place all over Europe – aims at highlighting this role by raising awareness and making biotech accessible to local communities and showing concrete examples to explain how biotech surrounds and supports us in everyday life. EuropaBio is delighted to launch the 10th edition of the European Biotech Week (#EBW2022)\, and to invite scientists\, companies\, academics\, students and policymakers to gather together physically or online and address ongoing challenges and find synergies for enhanced collaboration. \n\n\n\n\n\n\n\nGet involved: link your event or submit a thesisThe key to the success of the European Biotech Week is the active involvement of organisations\, companies\, and individuals. Any school\, university\, museum\, company\, institution\, association or organisation based in Europe is welcome to organise events as part of the Week. \n\n\n\nYou can become an official partner of European Biotech Week by linking your event to the Week – either during the Week or one week before or after. We will provide you with communications materials\, list your event on the European Biotech website and promote it on our social media channels. \n\n\n\nIf you are a student or a recent graduate you can take part in the Week by submitting your thesis on Industrial or Healthcare biotechnology topics. The Essay Competition is open to EU or Ukrainian citizens (or permanent EU residents) up to the age of 35. The winning essays will receive €1000 or €500 prizes. More details in the Rules\, Terms and Conditions.
URL:https://www.europabio.org/event/european-biotech-week-2022/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/04/Event-Banners.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220925T090000
DTEND;TZID=Europe/Brussels:20220928T180000
DTSTAMP:20260526T214420
CREATED:20220518T092049Z
LAST-MODIFIED:20220518T092902Z
UID:4721-1664096400-1664388000@www.europabio.org
SUMMARY:14th Carbohydrate Bioengineering Meeting (CBM14)
DESCRIPTION:Carbohydrate Bioengineering is recognized today as a pillar of biotechnology and biological engineering. It offers major assets to face many of our modern life challenges\, promote innovative medical treatments or elaborate functional food\, biopharmaceuticals\, active cosmetics\, biomaterials\, to name just a few. In particular\, researches in glycobiology\, multi-omic data integration\, structure/function relationships\, enzyme engineering\, biocatalysis\, biophysics and process development are key drivers to expand opportunities in this field. More than ever\, knowledge between carbohydrate players must be shared and crossing and bridging the disciplinary boundaries are essential to open new horizons of developments for the benefit of all. This will be the objective of CBM14. \n\n\n\nIn keeping with the previous CBMs\, the conference will bring together glycoscientists coming from all over the world to share their latest findings and most exciting achievements in a friendly and warm atmosphere. Experts from research institutions or private companies will open each session\, which will be followed by presentations selected from submitted abstracts. \n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/10th-international-congress-on-biocatalysis-biocat2022/
LOCATION:Oslo/Norefjell\, Norway\, Norway
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-8.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220828T090000
DTEND;TZID=Europe/Brussels:20220901T180000
DTSTAMP:20260526T214420
CREATED:20220524T101421Z
LAST-MODIFIED:20220524T101423Z
UID:4761-1661677200-1662055200@www.europabio.org
SUMMARY:10th International Congress on Biocatalysis (biocat2022)
DESCRIPTION:The transition from fossil to a biobased circular economy requires cutting edge technologies that ensure economic growth with environmentally responsible action.   \n\n\n\nThe future challenges which include utilization of natural resources\, food supply\, health\, energy and the environment\, can only be met in an interdisciplinary manner. \n\n\n\nBiocatalysis is one of the key technologies to address this complex task. Biotechnological products already find application in food\, feed\, chemical\, pharmaceutical and cosmetics industry and the developing sustainable bioeconomy is expected to create new processes and products and new job opportunities.   \n\n\n\nThe successful concept of biocat congress is aimed at integrating the know-how of highly acknowledged biologists\, biochemists\, chemists and engineers from academia and industry. Biocat congress offers a platform to form strategic alliances for future projects and innovations.   \n\n\n\nSince 2002 we have been organizing the biennial biocat conference series\, which is focused on the rapidly evolving fields of biocatalysis and industrial biotechnology. The preceding International Congresses on Biocatalysis attracted more than 3\,200 participants from over 40 countries. \n\n\n\n The major topics to be addressed are:  \n\n\n\nComputational analysis for enzyme discovery and designStructure-function analysis and enzyme optimizationEnzymatic and whole-cell biotransformationReaction cascades: Bioelectrochemical as well as chemo-/photoenzymaticBioprocess engineeringSynthesis of biodegradable materials and energy generationCarbon dioxide based biotechnologySustainable industrial processes\, biorefinery and bioeconomy\n\n\n\nIt is our aim to create a stimulating and open scientific atmosphere to foster the development of new collaborations.   \n\n\n\nIt is our great pleasure and honor to invite scientists from all over the world to the 10th International Congress on Biocatalysis 2022 (biocat2022) to be held from 28 August – 1 September 2022 at the Hamburg University of Technology (TUHH)\, Hamburg\, Germany. \n\n\n\nWe are looking forward to welcoming you in Hamburg\, an exciting and cosmopolitan city\, and to share a successful and enjoyable meeting in person with you. \n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/10th-international-congress-on-biocatalysis-biocat2022-2/
LOCATION:Hamburg University of Technology (TUHH)\, Am Schwarzenberg-Campus 1\, Hamburg\, 21073\, Germany
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-7.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220826T140000
DTEND;TZID=Europe/Brussels:20220826T160000
DTSTAMP:20260526T214420
CREATED:20220819T074007Z
LAST-MODIFIED:20220819T074008Z
UID:5045-1661522400-1661529600@www.europabio.org
SUMMARY:ESAB Webinar: Synthetic Biology and Metabolic Engineering Tools and Methodologies
DESCRIPTION:14:00-14:30Phage-assisted directed evolution of proteinsProf. Dr. Alfonso JaramilloInstituto de Biologia Integrativa de Sistemas (i2SysBio)\, CSIC\, Valencia\, Spain14:30-15:00 Engineered bacteria as an early-stage drug discovery platform for protein misfolding diseasesProf. Dr. Georgios SkretasDirector\, Institute for Bio-innovation\, Biomedical Sciences Research Center “Alexander Fleming”\, Athens\, Greece15:00-15:30Biochemical engineering drives the green transitionProf. Dr. Sotirios C. KampranisBiochemical Engineering Group\, Department of Plant and Environmental Sciences\, University of Copenhagen\, Frederiksberg C\, Denmark15:30-16:00 Cell-free synthetic biology enables industrial biotechnologyProf. Dr. Ashty KarimDepartment of Chemical and Biological Engineering and Director of Research for the Center for Synthetic Biology at Northwestern University\, Evanston\, IL 60208\, USA\n\n\n\n \n\n\n\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/esab-webinar-synthetic-biology-and-metabolic-engineering-tools-and-methodologies/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/08/2022-08-19-09_38_58-ESAB_Webinar_26AUGUST2022Flyer.pdf-Adobe-Acrobat-Pro-DC-64-bit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220729T090000
DTEND;TZID=Europe/Brussels:20220729T190000
DTSTAMP:20260526T214420
CREATED:20220726T091451Z
LAST-MODIFIED:20220726T091453Z
UID:5008-1659085200-1659121200@www.europabio.org
SUMMARY:Biocatalysis and Molecular Medcine
DESCRIPTION:ESAB and SKB are pleased to invite you to the Webinar on the new topic Biocatalysis and Molecular Medicine\, bridging the communities of biocatalysis/industrial biotechnology and molecular medicine. \n\n\n\n10:00 – 10:30 CESTCritical mechanisms in the pathogenesis of persistent bacterial infections Prof. Dr. Thomas F. MeyerMax Planck Institute for Infection Biology\, Department of Molecular Biology\, Berlin\, and Laboratory of Infection Oncology\, Institute of Clinical Molecular Biology\, Christian Albrecht’s University of Kiel and University Hospital Schleswig Holstein – Campus Kiel\, Germany10:30 – 11:00 CESTMucopolysaccharidoses – molecular mechanisms and treatment options of disorders caused by defects in biocatalysis of glycosaminoglycan decay  Prof. Dr. Grzegorz WegrzynDepartment of Molecular Biology\, Faculty of Biology\, University of Gdansk\, Wita Stwosza 59\, 80-308 Gdansk\, Poland11:00 – 11:30 CESTBiocatalysis in Cells through Proteolysis Targeting Chimeras (PROTACs): How to Improve Cell Permeability and Achieve Successful Protein Degradation Prof. Dr. Leonardo ScapozzaSchool of Pharmaceutical Sciences\, and Institute of Pharmaceutical Sciences of Western Switzerland\, University of Geneva\, Switzerland11:30 – 12:00 CESTThe use of systems biology in treatment of liver diseases Prof. Dr. Adil MardinogluScience for Life Laboratory\, KTH – Royal Institute of Technology\, Stockholm\, Sweden\, and Centre for Host-Microbiome Interactions\, Faculty of Dentistry\, Oral & Craniofacial Sciences\, King’s College London\, London\, United Kingdom\n\n\n\nESAB-SKB_Webinar_29JULY2022Download
URL:https://www.europabio.org/event/biocatalysis-and-molecular-medcine/
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/07/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220705T090000
DTEND;TZID=Europe/Brussels:20220708T180000
DTSTAMP:20260526T214420
CREATED:20220518T091432Z
LAST-MODIFIED:20220518T091433Z
UID:4714-1657011600-1657303200@www.europabio.org
SUMMARY:10th OxiZymes meeting
DESCRIPTION:Welcome to the 10th Edition of OxiZymes meeting!   \n\n\n\nInitially specifically devoted to research activities on laccases and peroxidases\, this series of conferences now cover the whole class of oxidoreductases. Building on the success of previous OxiZymes meetings\, OxiZymes 2022 will emphasize the discovery of new oxidoreductases and the latest advances in their biotechnological applications. The conference will provide a unique opportunity for industrial researchers to meet with foremost young academics for knowledge transfer and to establish research collaborations. The conference format is designed to be highly interactive\, with ample time for stimulating discussions\, interdisciplinary interactions\, and meetings alongside the scientific sessions. \n\n\n\nOxiZymes Siena will cover the following topics: \n\n\n\nNewly discovered OxizymesOxizymes mechanism and structureOxizymes engineering\, computational and biomimetic approachesOxizymes in fine chemistryBiotechnological applications of Oxizymes:Oxizymes in foodOxizymes in biorefineryOxizymes in biosensorsOxizymes in biomaterials applicationsSophie Vanhulle Prize 2022\n\n\n\nThe best poster and presentation will be awarded by MDPI with 200 CHF each. \n\n\n\nThe Organizing Committee is looking forward to welcoming you in Siena! \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/10th-oxizymes-meeting/
LOCATION:University of Siena\, Via Roma 56\, Siena\, 53100\, Italy
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220624T020000
DTEND;TZID=Europe/Brussels:20220624T160000
DTSTAMP:20260526T214420
CREATED:20220524T095433Z
LAST-MODIFIED:20220623T152259Z
UID:4758-1656036000-1656086400@www.europabio.org
SUMMARY:Biocatalytic and Sustainable Chemistry: Biocatalysis and Renewables
DESCRIPTION:The next webinar of the European Society of Applied Biocatalysis (ESAB)\, this time together with SusChem\, will take place on Friday\, 24 June 2022 (14:00-16:00 CEST). \n\n\n\nThe topic is “Biocatalytic and Sustainable Chemistry: Biocatalysis and Renewables”. \n\n\n\nYou can look forward to the following lectures: \n\n\n\n14:00 – 14:30 CESTBiocatalysis – Opportunities and challenges for industrial production Prof. Dr. Stefan Buchholz\, Head of R&D for the Division Nutrition & Care\, Evonik Operations GmbH\, Germany14:30 – 15:00 CESTBiotransformations as Key Steps in the Conversion of Unsaturated Fatty Acids into Industrial Chemicals Prof. Dr. Harald Gröger\, Department of Chemistry\, Industrial Organic Chemistry and Biotechnology\, Bielefeld University\, Germany15:00 – 15:30 CESTChemobiocatalytic upgrading of furfural to C4 chemicals Prof. Dr. Ning Li\, School of Food Science and Technology\, South China University of Technology\, Guangzhou 510640\, China15:30 – 16:00 CESTEnzymes for converting chitin/chitosans into highly valuable products Prof. Dr. Bruno Moerschbacher\, Institute of Plant Physiology and Ecology\, Münster University\, Germany\n\n\n\n \n\n\n\n \n\n\n\nPlease be informed\, that\, immediately after the registration\, you will receive an email confirmation with the Zoom link. \n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/9th-biorizon-annual-event-on-bio-aromatics/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/06/Event-Banners-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220615T200000
DTEND;TZID=Europe/Brussels:20220615T210000
DTSTAMP:20260526T214420
CREATED:20220505T095121Z
LAST-MODIFIED:20220510T112747Z
UID:4448-1655323200-1655326800@www.europabio.org
SUMMARY:EuropaBio: BIO 2022
DESCRIPTION:BIO 2022: The big bang in pharma legislation: A European epicentre shaping global healthcare and competitive industry \n\n\n\n\n\nEuropaBio is pleased to lead a panel discussion at BIO in San Diego and invites all delegates to join us to discuss the future of healthcare innovation as impacted by European changes. \n\n\n\n20 years ago\, European pharmaceutical legislation underwent a major review\, a critical point in the continent’s single market in healthcare.  Since then Europe has grown\, bringing new voices\, political momentum and advanced technologies into healthcare and today\, the European Commission is reshaping pharma legislation to meet the twin priorities of equality of access and ability to pay. \n\n\n\nThis is a significant moment for the global biopharmaceutical industry and one that will change the dynamics of investment\, science and market access for companies worldwide. \n\n\n\nHow does the legislative framework for medicines achieve its aims through reform? Balancing equity and affordability of medicines with reward for high-risk innovation from SMEs through to multi-nationals. \n\n\n\nPanel focus: \n\n\n\nThe drive for reform – the world is changing and with it must change the pathway for medicines so that all patients benefitWhat do SMEs\, mid-sized and multi-national companies need from legislation to ensure they can deliver innovation in the long term?When change is inevitable\, how does industry roll up its shelves and help collectively drive a new future\, rather than waiting for it to be imposed?How will European reform impact the global biopharma sector in a time of geopolitical realignment and regrowth?\n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/europabio-bio-2022/
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/inline_large_bio2022-linkedin-banner.jpeg
END:VEVENT
END:VCALENDAR